Hormonal therapy continues to be the treatment of to start with choice for metastatic patients with endocrine-responsive breast most cancers (LoE 1a A, In the past ++). The sequential use of the out there medicine is dependent upon the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at some time of prognosis of relapse is